Cidara Therapeutics, Inc. (NASDAQ:CDTX – Free Report) – Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Cidara Therapeutics in a report issued on Monday, March 10th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will post earnings of ($5.45) per share for the quarter, down from their prior estimate of ($5.13). HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Cidara Therapeutics’ current full-year earnings is ($8.74) per share. HC Wainwright also issued estimates for Cidara Therapeutics’ Q2 2025 earnings at ($1.08) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($7.12) EPS, FY2026 earnings at ($14.64) EPS, FY2027 earnings at ($16.66) EPS and FY2028 earnings at ($4.73) EPS.
A number of other equities analysts have also recently commented on CDTX. Royal Bank of Canada initiated coverage on Cidara Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $34.00 price objective for the company. JMP Securities set a $46.00 price objective on Cidara Therapeutics in a report on Wednesday. Citigroup initiated coverage on Cidara Therapeutics in a report on Wednesday. They set an “outperform” rating for the company. Cantor Fitzgerald upgraded Cidara Therapeutics to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $35.00 price objective on shares of Cidara Therapeutics in a report on Friday, March 7th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Cidara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $39.14.
View Our Latest Stock Report on CDTX
Cidara Therapeutics Stock Performance
Cidara Therapeutics stock opened at $22.36 on Wednesday. Cidara Therapeutics has a 52 week low of $10.00 and a 52 week high of $28.42. The stock has a market capitalization of $157.57 million, a P/E ratio of -0.88 and a beta of 0.88. The stock has a 50-day simple moving average of $22.27 and a 200 day simple moving average of $17.67.
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($5.38) EPS for the quarter, missing analysts’ consensus estimates of ($5.28) by ($0.10). Cidara Therapeutics had a negative return on equity of 69.64% and a negative net margin of 289.05%.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Cidara Therapeutics during the fourth quarter valued at approximately $56,000. Point72 Asset Management L.P. acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth $165,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth $339,000. Jane Street Group LLC acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth $342,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth $419,000. 35.82% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Cidara Therapeutics
In other Cidara Therapeutics news, COO Shane Ward sold 1,664 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $21.96, for a total transaction of $36,541.44. Following the completion of the transaction, the chief operating officer now directly owns 14,674 shares in the company, valued at $322,241.04. The trade was a 10.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Leslie Tari sold 1,773 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $21.96, for a total transaction of $38,935.08. Following the transaction, the insider now owns 16,215 shares of the company’s stock, valued at approximately $356,081.40. This represents a 9.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.64% of the stock is currently owned by corporate insiders.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Featured Articles
Receive News & Ratings for Cidara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cidara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
